Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
15/04/2025 16:27
April 15 (Reuters) - Eisai Co Ltd 4523.T: BIOARCTIC AB - EU APPROVES LEQEMBI® (LECANEMAB) FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nWkr3hfLqX Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million